Statins and PCSK9 Inhibitors: How They Have Shaped Medicine, A Comparative Review
Date of Award
Internship Practicum Report
Master of Science
Field of Study
Clinical Research Management
Graduate School of Biomedical Sciences
Rustin E. Reeves
Patricia A. Gwirtz
Keeping serum low density lipoprotein cholesterol (LDL-C) levels within recommended ranges has been proven to lower the risk of cardiovascular events from occurring. To lower LDL-C levels, statins have been the drug of choice for the last few decades since they were introduced. However, the discovery of PCSK9 inhibitors and new knowledge about how they are able to lower LDL-C levels may provide physicians a new path to consider when choosing a course of treatment in patients that fit the criteria for PCSK9 inhibition. Furthermore, there are several risks with statins which may turn physicians towards using PCSK9 inhibitors in patients with uncontrolled LDL-C. This practicum report is a review of the latest developments in PCSK9 drugs and how they compare to statins in lowering LDL levels.
Escarsega, P. R.
"Statins and PCSK9 Inhibitors: How They Have Shaped Medicine, A Comparative Review" Fort Worth, Tx: University of North Texas Health Science Center;
This document is currently not available here.